Cipla has received an approval for transfer of the consumer healthcare business of the company to Cipla Health on a going concern basis by way of a slump sale for a lump sum consideration of Rs 16 crore. The board of directors at their meeting held on December 10, 2015 has approved for the same.
Cipla Health is a newly incorporated subsidiary of the company and was incorporated on August 27, 2015. It will focus its business activities in the consumer healthcare space. The consumer healthcare business to be transferred to Cipla Health includes the scope of the business as approved on July 09, 2015, along with certain additional business.
The amount and percentage of the turnover contributed by the consumer healthcare business of the company for the financial year 2014-15 was Rs 54.28 crore and approximately 0.48% respectively. The net worth of consumer healthcare business of the company as on March 31, 2015 was Rs 7.88 crore contributing 0.07% of the net worth of the company.
The transaction will enable the company to participate in the attractive and growing over-the-counter market. This business requires a specialized FMCG kind of focus, and a separate subsidiary would enable the company to attract the right talent and provide the focus and attention required for this business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |